Recently, it was found that the AR to ER ratio in breast cancer influences the sensitivity to AR-targeted treatments, suggesting the potential utility of enzalutamide in ER+ tumors with a low AR/ER ratio and AR agonists like RAD140 in those with a high AR/ER ratio [176]. The gene discussed is ESR1; the disease is breast carcinoma.